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[α]D: specific rotation at wavelength of sodium D line  
Ac: acetyl 
AcOH: acetic acid 
Aq.: aqueous 
Boc: tert-buthoxycarbonyl 
BSA: Bovine Serum Albumin 
Bu: butyl 
C1P: ceramide-1-phosphate 
CA: caproic acid 
Cer: ceramide 
ºC: degrees Celsius 
DDQ: 2,3-dichloro-5,6-dicyano-p-benzoquinone 
DMEM: Dulbecco’s Modified Eagle Medium 
DMF: N,N-dimethylformamide 
DMP: dimethoxypropane 
DMSO: dimethylsulfoxide 
FRET: Förster resonance energy transfer 
GlcCer: glucosylceramide  
hv: light 
HBSS: Hepes-buffered saline solution 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hz: hertz 
HRMS: high resolution mass spectroscopy  
i-Pr: isopropyl   
IR: infrared 
KFL5: 
LC-MS/MS: liquid chromatography/mass spectrometry 
LHMDS: lithium hexamethyldisilazane 
M: molar (moles per liter) 
Me: methyl 
MS: molecular sieves 
N B N
OO
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N
O
N
NO2
NBD: 
NBS: N-bromosuccinimide 
NIS: N-iodosuccinimide 
nm: nano meter 
NMR: nuclear magnetic resonance  
p: para 
PAL: photoaffinity labeling 
PMT: photomultiplier tube sensitivity 
PPIs: protein-protein interactions 
PPMP: D-threo-1-Phenyl-2-hexadecanoylamino-3-morpholino-1-propanol•HCl 
quant.: quantitative yield 
S1P: sphingosine-1-phosphate 
sat.: saturated 
SKI-II: SphK1 inhibitor II 
SM: sphingomyelin 
SPh: sphingosine 
t-BuLi: tert-butyl lithium  
Tf: trifluoromethanesulfonyl 
TFA: trifluoroacetic acid 
THF: tetrahydrofuran 
TLC: thin-layer chromatography 
TMS: trimethylsilyl
Ts: p-toluenesulfonyl 
UV: ultraviolet
     In this dissertation, I describe my research on the development of new bioprobes.  Bioprobes are 
some small molecular weight compounds which are useful for reveal molecular mechanisms of 
eukaryotic cells. They are usually organic compounds which can not only be isolated from natural 
sources but also obtained by organic synthesis. Several labeling methods have been developed to 
obtain more convenient bioprobes. My research work focuses on fluorescent labeling and 
photoaffinity labeling. Fluorescent labeling can be performed in real-time and sensitivity down to 
single molecules, while Photoaffinity labeling has become one of the most powerful strategies to 
study Protein-protein interactions. Chapter one provides a study on the development of new 
fluorescent ceramide probes with KFL5 and NBD, especially a doubly-labeled ceramide probe 
about their synthesis, optical properties, and bioactivity. Chapter two discusses a synthetic study on 
Lundurine B probes with photoaffinity labeling, including preparation for a key intermediate in the 
total synthesis of Lundurine B and halogenation of it. 
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ABSTRACT
  6
CHAPTER ONE:  
Development of New Fluorescent Ceramide Probes
1.1 Introduction 
1.1.1 Sphingolipids 
    Sphingolipids are a family of natural lipids which have a same base backbone, sphingosine.1 
They are significant constituents of cellular membranes representing the function in membrane 
structural integrity (Fig. 1). However, some of them also act as signaling molecules in various 
cellular processes. In this highly integrated metabolic network among various bioactive 
sphingolipids, accumulation or reduction of members in this family may result in changes in 
metabolite levels, enzyme activities, and cellular programs, which may trigger pathology of many 
diseases. 
     Similar to other compound classes, confirmation of biochemical mechanisms of sphingolipids 
always hold promise for the development of novel drugs for fighting human disease. Many groups 
are concentrating the study on sphingolipids. Among the various sphingolipids, ceramide is 
considered the central molecular because cleavage of the N-acyl moiety of ceramide is a crucial 
transformation in the metabolism, which generates sphingosine, a important bioactive molecular. 
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Figure 1. Metabolism of sphingolipids
Sphingosine (Sph) can be further converted to another critical signaling molecular sphingosine-1-
phosphate (S1P).2 These signaling intermediates have been studied to understand their function in 
cellular processes, such as apoptosis, proliferation, and differentiation. 
 Although in the last 40 years many studies on the mechanisms that regulate lipid generation and 
lipid action decipher the function of lipids in cellular processes, there are still need more 
concentration on sphingolipid. 
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1.1.2 Fluorescent Ceramide Probe 
   To investigate the metabolism of sphingolipids, several chemical biology tools have been 
developed.3 Among them, fluorescence labeled ceramides have recently attracted much research 
attention with advantages of high sensitivity and specificity. Although MS is a more convenient 
method to quantify ceramide and its metabolites, fluorescence labeled ceramides can be still 
considered the robust and flexible real-time assays for clarifying the activity of enzymes and 
tracking the metabolism. Over recent years, different labeled fluorescent ceramide probes have been 
developed, with NBD, BODIPY, and coumarin as the fluorescent group, which are introduced into 
either the acyl chain or alkyl chain of ceramide structure (Fig. 2). In our previous report, we 
developed a new fluorescent ceramide probe, acetyl-C16-ceramide-NBD, which has a core structure 
of ceramide.4  Compared with the commercially available and widely used Golgi marker C6-NBD-
ceramide,5 this fluorescent ceramide analogue shown better stability in bioconversion and was able 
to be used as a long-term Golgi marker. 
       However, only with the singly-labeled ceramide probes, unlabeled parts of ceramide structure is 
hard to be detected. In 2013, Arena et al. reported the development of Förster resonance energy 
transfer (FRET) ceramide probes (3a and 3b), having NBD as a donor and Nile Red as an acceptor.6 
They also examined new probes’ bioactivity for ceramidase by a real-time measurement in vitro. 
Although fluorescence derived from these probes was successfully detected in the Golgi apparatus, 
cleavage of an amide bond triggered by ceramidase was not observed in living cells. So, we decided 
to design a new doubly-labeled fluorescent ceramide probe 1.  
     In our plan for  a doubly-labeled ceramide probe, we decide to introduce a NBD fluorophore into 
an acyl side chain by reason that C6-NBD-ceramide is a commercially available and well-
established Golgi marker. We chose a BODIPY-type fluorophore called KFL5 which is developed 
by Suzuki et al.,7 as the second fluorophore in an alkyl main chain. KFL5 is reported as an excellent 
fluorophore because of its high brightness, high quantum yield, sharp emission spectra and robust 
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structure.8 In terms of their fluorescence spectra, the emission wavelength of NBD are separate with 
the  absorption band of KFL5.  Because of the little overlap in the spectra of these two fluorophores, 
we expected that it is possible to observe red and green fluorescence from both KFL5 and NBD by 
only using probe 1. We also developed some new singly-labeled fluorescent ceramide probes with 
NBD or KFL5 (2a, 2b, 2c). 
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Figure 2. Fluorescent ceramide probes
1.2 Synthesis of New Fluorescent Ceramide Probes With NBD and KFL5  
     Referring to previous paper,9 the cross metathesis reagent of alkene partner 5 was synthesized by 
the indium-catalyzed condensation from furopyrrole 410 and 10-undecenal,11 which was converted 
to 5 by a widely used method in bodipy synthesis. Then we started to introduce KFL5 into the alkyl 
chain of ceramide with 5. 
    Cross metathesis was a suitable reaction to obtain 1 between N-acylated alkene 7 which is 
obtained from known 6, and 1-decene derivative 5. After the deprotection of acetal, we obtained 
doubly-labeled fluorescent ceramide probe 1. 
            New singly-labeled ceramide probes with KFL5 or NBD were also synthesized by the same 
procedure. Then, we also synthesized sphingosine-KFL5 by a similar procedure which is prepared 
for the following bioactivity investigation.  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1.3 Measurement of Optical Properties 
     With these singly- and doubly-labeled fluorescent ceramide prepared, we first confirm their 
optical properties by fluorescence spectroscopy. Figure 3 shows the compare of the absorption and 
emission spectra of 1 with those of 2a, 2b, 5 and KFL5 itself. In Figure 3A and 3B, absorption and 
emission spectra of singly-labeled ceramide probes 2a and 2b including KFL5 in a ceramide main 
chain, displayed almost the same characteristics compared to those of 5 and KFL5 when excited at 
648 nm. However, when we watched the orange line representing doubly-labeled 1 in figure 3B, 1 
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Figure 3. Absorption and emission spectra of 1, 2a, 2b and 5. These emission 
spectrum were obtained when excited at 648 nm. Emission spectrum of KFL5 was 
were obtained when excited at 653 nm. All spectra were measured in chloroform.
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Figure 4. Emission spectra of 1 and 2c. These emission spectra were obtained when 
excited  at 469 nm. All spectra were measured in chloroform.
A
B
Dye λabs (nm)
ε 
(M-1cm-1) φ 
c)
652 661 314000 0.90 282600
653 657 313000 0.82 256660
1 648 653 274400 0.71 194824
469 515/652 28100 0.02 562
2a 648 653 304500 0.86 270900
2b 648 652 315000 0.92 289800
2c 463 520 28400 0.52 14768
λem
a
(nm)
Brightnessb 
(M-1cm-1)
KFL-5c
KFL-5
648 652 305000 0.99 265250
Table 1. Optical properties of 1, 2a, 2b, 2c, 5 and KFL5 in chloroform. a Excitation 
wavelength; 1 (469 and 648 nm), 2a, 2b, 5 (648 nm), 2c (463 nm) and KFL5 (653 nm). b 
Brightness is defined as ɛ × ø. c From Ref. 7a. 
5
performed only half the intensity when excited at the same wavelength, 648 nm. In the next, we 
checked the emission spectra of 1 when excited at 469 nm, the NBD’s absorption. When excited at 
469 nm, emission bands from NBD (515 nm) and KFL5 (652 nm) in 1 were both observed (Fig. 
4A), which could indicate that there is a partial energy transfer from NBD to KFL5. The 
fluorescence intensity of NBD decreased considerably to 4% when we compared 1 with 2c’s 
emission spectrum (Fig. 4B). In summary, figure 4 shows that there is a cross quenching effect 
between NBD and KFL5 in 1. The optical properties of 1, 2a, 2b, 2c, 5 and KFL5 are summarized 
in Table 1. Table 1 shows that these fluorophores with KFL5 have similar quantum yield, which 
means the stability of KFL5 structure. Because the cross quenching effects between KFL5 and 
NBD, the brightness of the fluorescence from them in 1 was less than those of 2a and 2c. However, 
1 still showed bright fluorescence at 652 nm when compared with 2c. 
     Next, we used TLC analysis to confirm the fluorescent characteristic of 1 comparing with two 
fluorophores, NBD-caproic acid (C6-fatty acid, NBD-CA) and sphingosine-KFL5 (Sph-KFL5) in a 
quantitative manner (Table 2). Meanwhile, NBD-caproic acid and sphingosine-KFL5 also 
represents the metabolites from 1 under ceramidase. Table 2A shows that fluorescence of NBD in 1 
increased almost linearly in a dose-dependent fashion until 100 pmol. However, at any of the 
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A) NBD fluorescence (excitation; 520-540 nm);  
  NBD-CA                         1a 
 25 pmol     1,925,230  12,491 (0.64) 
 50 pmol     3,147,990  25,426 (0.80) 
 100 pmol    6,593,926 45,819 (0.69) 
B) KFL5 fluorescence (excitation; ≥ 665 nm);  
  Sph-KFL5       1b  
 25 pmol 22,637 4,622 (20.4) 
 50 pmol 47,402 6,856 (14.4) 
 100 pmol 89,430 6,661 (7.4) 
Table 2. Comparison of fluorescence intensity between 1, NBD-CA and Sph-KFL5 
by TLC analysis. a Numbers in parentheses show intensity ratio (%) of 1/NBD-CA. b 
Numbers in parentheses show intensity ratio of 1/Sph-KFL5. 
examined amounts their intensity was less than 1% of that in NBD-CA. Performing in a different 
way, the intensity of KFL5 fluorescence in 1 stoped increase at the concentration of 50 pmol. 
Meanwhile, at 25 pmol the intensity of KFL5 fluorescence in 1 performed 20% of that of Sph-
KFL5 and  at 50 pmol the intensity of KFL5 fluorescence decreased to 14% of that of Sph-KFL5. 
Correspond to the former results of the fluorescence spectra, the mutual quenching effect of 
fluorescence in 1 also displayed in TLC analysis, which  may be one of its essential features 
because the spots NBD-CA acid and Sph-KFL5 on a TLC performed steadily even when they 
located in same place. These results told us that the presence of KFL5 and NBD in the same 
molecule leads to fluorescence quenching effects that KFL5 markedly decreases the intensity of 
NBD fluorescence (less than 1%) because of the energy transfer, and KFL5 was also influenced by 
NBD which cause KFL5 fluorescence decrease to approximately 20% in 1. The result of the TLC 
analysis corresponds with the measurement of UV spectra. 
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1.4 Bioactivity Investigation 
1.4.1 Cell Membrane Permeability 
     In live cells treated with 1 uM 1, 2a, 2b, 2c and C6-NBD-Cer at 37 °C in 30 min, the observation 
was measured by Zeiss LSM 780 microscopy and Olympus confocal imaging microscopy.4, 12 Probe 
1 was taken up into cells and the fluorescence derived from NBD or KFL5 was weakly observed in 
the area close to the nucleus and the Golgi complex. Probe 2a was also taken up into cells, while 2b 
was not detected in cells. Probe 2c showed a similar uptake compared with C6-NBD-ceramide. 
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1.4.2 Observation of Fluorescent Images of Fixed Cells 
     Next, we measured a real-time observation of fluorescent images of probe 1. At first, we used 2a 
and C6-NBD-ceramide as control groups. In live cells treated with 10 uM C6-NBD-ceramide at 37 
°C, after treatment at 1 hr the green fluorescence derived from NBD mainly appeared in the area 
around the nucleus and the Golgi complex as described previously.12 The accumulation of NBD 
fluorescence in the Golgi complex could be observed clearly at 2 hr and was still detected at 4 hr 
after C6-NBD-ceramide treatment (Gain: 700). When treating cells with 10 uM 2a, 2a was also 
taken up and accumulated in the Golgi complex in a similar ways (Gain: 500, Fig. 6B).  
    When treating cells with doubly-labeled ceramide probe 1, the result shows an obvious contrast 
to these two ceramide analogs labeled with either NBD or KFL5 that 1 performed a very low 
uptake. Although we increased concentration of 1 to 50 uM in cells treatment, fluorescence in living 
cells was not detected within 1 hr after treatment. Then KFL5 fluorescence (Gain: 500) was 
detected at 2 hr after treatment and appeared to increase in a time-dependent manner until 4 hr after 
treatment specifically in the Golgi complex (Fig. 6C). NBD fluorescence (Gain: 700) was slightly 
observed at 2 hr, and the intensity of NBD fluorescence in the Golgi complex accumulated and 
increased at 4 hr after treatment (Fig. 6C). These results tell us that 1) 1 was time-dependently taken 
up in cells, although the uptake was much less than those of singly-labeled ceramide analogs such 
as C6-NBD-Cer or 2a. 2) similar to other ceramide probes, 1 was also accumulated in the Golgi 
complex. On the merged image of cells at 4 hr after treatment with 1, weak singly green 
fluorescence marked by the white arrow and weak singly red fluorescence marked by the white 
triangle were detected in the nucleus and/or in the area close to the plasma membrane in some cells. 
Considering that NBD fluorescence markedly decreased by KFL5 in 1, the weak green fluorescence 
may represent NBD-CA and/or its metabolites in cells and the weak red fluorescence may represent 
sphingosine-KFL5 and/or its metabolites in cells. The singly red or green fluorescence could also 
indicate that 1 was successfully metabolized in living cells.  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Figure 6. Images of 1, 2a and C6-NBD-ceramide in COS-7 Cells. a COS-7 cells were incubated 
with 10 uM C6-NBD-Cer (A), 10 uM 2a (B), and 50 uM 1 (C) for the indicated periods at 37 °C, 
and then washed with ceramide-free buffer. Images of the cellular distribution were analyzed at 
the same intensities (Gain, 700 for NBD and Gain, 500 for KFL5) with the same contrast (low 0 ~ 
high 20,000) under the following conditions; 473 nm excitation and 520-540 nm emission for 
NBD, 635 nm excitation and ≥665 nm emission for KFL5. Images in the panels on the right in C 
were taken at an enhanced contrast (low 0 ~ high 10,000) and the vertical axis shows the relative 
fluorescence intensity. 
C
NBD 
KFL5 
1.4.3 Analysis of Metabolites from Probe 1 
     Since we found that probe 1 would be metabolized in living cells, we tried to understand the 
metabolism of  1. In cells treated with 50 µM of 1 in 4 hours, several new compound was detected 
by TLC analysis (Fig. 7). According to previous research, several metabolites was possibly 
conjectured such as sphingosine (Sph),  glucosylceramide (GlcCer) and sphingosine-1-phosphate 
(S1P). These results correspond to the results of observation of fluorescent images, which means 1 
was metabolized in living cells. 
          
        
     To make a further confirmation of these metabolites, we took advantages of two compounds, 
PPMP, an inhibitor of glucosylceramide synthase13 and SKI-II, an inhibitor of sphingosine kinase14. 
At first, we incubated COS-7 cells with 50 uM 1 and 5 uM C6-NBD-Cer for 4 hr co-incubating 
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with PPMP in different concentration, respectively. Then, we collected ceramide metabolites from 
both cells and compared them by TLC analysis. As previous report when cells were incubated with 
C6-NBD-Cer, the formation of C6-NBD-glucosylceramide (C6-NBD-GlcCer) and C6-NBD-
sphingomyelin (C6-NBD-SM) was confirmed by green fluorescence on TLC (Fig. 8A). It is shows 
that co-incubation with PPMP markedly inhibited the formation of C6-NBD-GlcCer as previously 
reported.14 However, red fluorescence was not detected in treating cells with 5 uM C6-NBD-Cer 
(Fig. 8B). When treating cells with 50 uM of 1, formation of metabolites, SM and GlcCer was only 
detected weakly through green fluorescence, probably because of cross-quenching of NBD/KFL5 as 
described before. On the other hand, many bands having red fluorescence appeared clearly on TLC 
plate which could be identified as some major metabolites referring to previous report.14 We 
detected two bands (Rf values 0.7-0.8) on TLC, which are lower than native 1 (Rf value 0.9) and 
higher than another major band (Rf value 0.7). Fluorescence intensity of these two bands (Rf values 
0.7-0.8) were markedly decreased by co-incubation with PPMP, which may mean that these bands 
appeared to be GlcCer and/or GlcCer-derived metabolites. 
     The result of SKI-II co-incubations on ceramide metabolism in 1 is shown in Fig. 8C. After 
treating cells with SKI-II the Rf-0.7 band increased and Rf-0.5 band decreased, respectively, in a 
concentration-dependent manner, which means that the Rf-0.7 band was identified to be Sph-KFL5 
and Rf-0.5 band represented S1P-KFL5. The intensity of the bands that represented SM (Rf-0.3) 
and GlcCer and/or its metabolites (Rf values 0.7-0.8) increased in in a concentration-dependent 
manner (Fig. 8C and 9). These increases and decreases can be explained by the ceramide 
metabolism pathway as described in the instruction sections. These results showed that 1 was 
successfully metabolized in live cells and transferred to sphingosine, S1P, SM and GlcCer, in intact 
cells. 
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**
C
*
Figure 8. TLC Analysis of Metabolites from 1 by inhibitors. a A) and B); COS-7 cells 
were cultured with DMEM containing 10 % serum in 12-well plates to a sub-confluent 
stage (70-80% confluent). The cells were pretreated with vehicle (0.02% DMSO) or 
PPMP at 5 and 10 uM for 30 min, and then treated with 50 uM of 1 or 5 uM C6-NBD-
Cer for an additional 4 hr. The lipids extracted were separated by TLC. Fluorescence of 
NBD and KFL5 is shown in the left and right panels, respectively. C); Inhibition of 
sphingosine-KFL5 formation in COS-7 cells by SKI-II, an inhibitor of sphingosine 
kinase.14 The cells were pretreated with vehicle or SKI-II at 2.5, 5 and 10 uM for 30 
min, and then treated with 50 uM of 1 for an additional 4 hr. The lipid extracts were 
separated by TLC. Fluorescence of KFL5 appears as red and black in the left and right 
panels, respectively. Numbers in parentheses show the Rf values on TLC analysis in 
panel C. [*] in panel A and [**] in panels B and C are contaminated (or degradation) 
products having NBD and KFL5 in a solution of 1, respectively.
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Figure 9. Relative fluorescence intensity of metabolites detected on TLC by treating 
cells with SKI-II in different concentration. 
1.5 Discussion  
      In the ceramide metabolism pathway, there are four important enzymes ; sphingomyelin (SM) 
synthase, which produces SM, glucosylceramide (GlcCer) synthase, which produces GlcCer, 
ceramide kinase, which produces ceramide-1-phosphate (C1P), and ceramidase, which produces 
sphingosine and fatty acid.15 Sphingosine is further metabolized to sphingosine-1-phosphate (S1P), 
a lipid signaling mediator, by sphingosine kinase. In many ceramide researches, commercially 
available probe, C6-NBD-Ceramide has been widely used to monitor levels of C6-NBD-SM, C6-
NBD-GlcCer, C6-NBD-C1P, and NBD-CA,3, 13, 16 but it is hard to detect the unlabeled parts 
deriving metabolites, Sph and S1P and determine their exact levels.  
          In this study, we have synthesized a doubly-labeled fluorescent ceramide probe 1 and new 
singly-labeled ceramide probes 2a, 2b and 2c. Ceramide analogs 1, 2a and 2b have a bright 
fluorophore, KFL5, in an alkyl chain. Because of  mutual quenching effect between NBD and KFL5 
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Figure 10. New fluorescent ceramide probes.
Figure 11. Observed metabolism of 1.
fluorophores in 1, their fluorescence were weaker compared with those in singly-labeled 2a and C6-
NBD-Cer. However, we observed the uptake of 1 in living cells by microscope and detected some 
metabolites from 1 were detected by simple TLC analysis, which enabled the measurement of 
GlcCer, SM, sphingosine, and S1P in a single preparation of cells. Therefore, 1 should be a useful 
and convenient probe for monitoring the metabolism of sphingolipids in cells. Further studies will 
be needed on the structural modification of 1 to promote its rapid uptake in cells and bright 
fluorescence.  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CHAPTER TWO:  
Synthetic Study On Lundurine B with  
Photoaffinity Labeling
2.1 Introduction 
2.1.1 Lundurine B 
     Lundurine B belongs to a group of lundurine alkaloid, which is isolated from Malaysian Kopsia 
tenuis in 1995. Having intriguing hexacyclic framework includes an unprecedented 
cyclopropa[b]indole, lundurine B shows strong anti-melanoma activities and reverses multi-drug 
resistance in vincristineresistant KB cells,17 which suggests that it is necessary to do further 
biomedical study on lundurine B. To dissolve the availability of lundurine B, our lab has 
accomplished the total synthesis of lundurine B by Dr. Hoshi18 and Dr. Nakajima19.         
    However, discovering new drugs needs further study to explore the bioactivity of lundurine B 
such as Protein-protein interactions (PPIs) related to lundurine B, probes based on the structure of 
lundurine B are essential to be developed. 
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2.1.2 Photoaffinity Labeling (PAL) 
     To study specific proteins related to the bioactivity of lundurine B, there are several techniques 
including affinity chromatography, activity-based probes, affinity-based probes and photo-affinity 
labeling (PAL).20 Among them, PAL has become one of the most powerful strategies to study PPIs. 
       PAL was developed by Westheimer et al. in 1962.21 To realize localization and trafficking of a 
protein of interest, photoaffinity probes are always introduced with two functional groups. One is a 
photocrosslinking group such as diazirine, benzophenone, aryl azide that can generate reactive 
intermediates to form a new covalent bond between the probe and its target protein through a 
photoirradiation. The other one is a detectable tag to distinguish the photolabeled protein from 
unlabeled ones.22 
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Figure 12. Process of photoaffinity labeling (PAL)
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Figure 13. Model of action of different photocrosslinkers
       To carry out the lundurine B’s structure-function studies of biological systems, we try to 
develop photoaffinity labeling probes based on the structure of lundurine B. 
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Figure 14. Plan for lundurine B probe.
2.2 Synthesis of Key Intermediate 
      In 2016, Dr. Nakajima reported the enantioselective total syntheses of the Kopsia alkaloids (+)-
grandilodine C and (+)-lapidilectine B,23 in which a 3 steps synthesis of spirodiketone 15. With 
starting material 16, we considered that the key intermediate 17 in the total synthesis of lundurine 
alkaloids could also be prepared according to the reported procedure. At first, we started to 
synthesize the reagent 16. On step iodination with 4-methoxyaniline 18 didn’t proceed at all 
whether using iodine or NIS, which may be explained by the instability of 4-methoxyaniline 18. 
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Scheme 4. Synthesis of key intermediate in total syntheses of  (+)-grandilodine C 
and (+)-lapidilectine B.
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O
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Scheme 5. Plan for synthesis of key intermediate 17.
entry
1
2
3
conditions
NaHCO3, I2 (powder), H2O, 10 oC
NaHCO3, I2 (solid), H2O, 10 oC
NIS, AcOH, r.t.
Ag2SO4, I2, r.t.4
results
complicated mixture
complicated mixture
N.R.
N.R.
NH2
MeO
18
NH2
MeO I
16
Table 3. First attempt for obtaining 16 
     In the next, we protected the amine group of 4-methoxyaniline 18 under the ultrasound condition 
to dissolve the instability problem. According to the reported procedure,25 continuing iodination of 
19  succeeded by reaction with 1,2-diiodoethane, which was converted to 16 through a deprotection 
of boc group with TFA. 
     With the starting material 16 prepared, the key intermediate 17 was also successfully synthesized 
refer to the reported procedure, followed by acetalization of the less-hindered carbonyl group. 
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Scheme 6. Second attempt for obtaining 16 
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Scheme 7. Preparation of key intermediate 17 
2.3 Halogenation of Key Intermediate 
     To introduce the photoreactive group into lundurine B, a spacer is needed between them. So we 
decided to attempt some coupling reaction with halogenated lundurine B (Table 4). For decreasing 
the changes of bioactivity as much as possible,  we chose to do halogenation at the benzene cycle in 
lundurine B. However, it is necessary to make model reaction before the synthesis of lundurine b 
probes. So, we discussed the halogenation of the key intermediate 17. We tested the halogenation 
with NIS26 and NBS27 firstly. These results suggested that there could be some effects from p-
methoxy group or carbamate group, no halogenation proceeded with NIS or NBS at the different 
temperature. More conditions of halogenation will be tested in the future.  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X
Table 4. Halogenation of 17. Entry 1~5, NBS. Entry 6~10, NIS. 
2.4 Attempt for Total Synthesis of Lundurine B 
     We also tried the total synthesis of lundurine B19 starting with intermediate 17. Addition of an 
alkynyl lithium reagent to a benzylic carbonyl group gave 25, followed by a Cu-catalyzed Meyere-
Schuster rearrangement. In contrast with the reported result, the single product wasn’t obtained. 
However, both E olefin product and Z olefin product appeared, which was hard to be separated by 
flash column chromatography. As a result, it is difficult to synthesize 29 which is a known 
intermediate in the total synthesis of lundurine B. 
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Scheme 7. Attempt for total synthesis of lundurine B. 
2.5 Summary 
       The key intermediate 17 in the total synthesis of lundurine B was synthesized in an efficient 
procedure. However, halogenation of 17 didn’t proceed and attempt for the total synthesis staring 
from 17 also failed.    
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Experimental Section 
 Materials and Methods     
     All reactions involving air- or moisture-sensitive reagents or intermediates were 
performed under an inert atmosphere of argon in glassware. Unless otherwise noted, 
solvents and reagents were reagent grade and used without purification. Anhydrous 
Dichloromethane, tetrahydrofuran and toluene were purchased from Kanto Co. Ltd. 
Reactions were monitored by thin-layer chromatography carried out on 0.25 mm Merck 
silica gel plates (60F-254). Column chromatography was performed with silica gel (Fuji 
Silysia, PSQ-60B) or NH-silica (Fuji Silysia, DM2035). NMR spectra were recorded on 
spectrometers of JEOL-JMN-ECS-400, ECP-400 and ECA-600 operating at 400 and 600 
MHz for 1H NMR, 100 MHz for 13C NMR in CDCl3 with calibration using residual 
undertreated solvent as an internal reference. IR spectra were recorded on a JASCO FT/
IR-230 Fourier transform spectrophotometer. Mass spectra were recorded using JEOL JMS-
T100LP for HRMS. Melting points were determined on AZ ONE melting point apparatus 
ATM-02. 
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Chapter One 
1) Synthesis of Materials  
10: For cross-metathesis reaction, a mixture of 6 (7.2 mg, 0.029 mmol) and 5 (16.3 mg, 0.029 
mmol) in CH2Cl2 (0.02 M, Ar Bubbling) was prepared. After addition of 2nd generation Grubbs’ 
catalyst (4.7 mg, 20 mol%), the reaction mixture was allowed to reflux for 3 hours. The mixture 
was filtrated through a pad of NH-silica and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography (Hexane/EtOAc = 4/1) to give 10 (13.4 mg, 
61%). [α]D25 -0.11 (c 0.70, CHCl3). 1H NMR: δ7.80 (m, 4H), 7.43 (m, 6H), 6.95 (s, 2H), 6.67 (s, 
2H), 5.75 (dt, J = 15.2, 6.4 Hz, 1H), 5.45 (dd, J = 15.2 Hz, 6.4 Hz, 1H), 3.88-4.24 (m, 4H), 2.84 (m, 
2H), 2.03 (m, 2H), 1.81 (quin, J = 7.6 Hz, 2H), 1.26-1.54 (m, 25H); 13C NMR: δ 167.6, 153.3, 
149.3, 145.3, 139.6, 133.3, 130.1, 129.9, 129.1, 125.5, 100.4, 95.6, 94.5, 74.3, 64.8, 62.3, 33.9, 
32.4, 30.8, 30.1, 29.7, 29.4, 29.2, 29.1, 28.4, 26.4, 24.7, 22.7, 14.3; HRMS (ESI): m/z calcd for 
C46H52BF2O6N3Na [M+Na]+ 814.38149, found 814.38042. IR (ATR): 2925, 2852, 1695, 1568, 
1400, 1083 cm-1. 
Sphingosine-KFL5: 10 (6.0 mg, 0.008 mmol) was added 4N HCl/dioxane (0.02 M) and the 
mixture was stirred at room temperature for 30 minutes. After concentration under reduced presure, 
the crude material was purified by flash column chromatography (NH silica, CHCl3/iPrOH) to give 
Sphingosine-KFL5 as a blue film (2.3 mg, 47%). [α]D25 +2.79 (c 0.075, CHCl3). 1H NMR: δ7.80 
(m, 4H), 7.45 (m, 6H), 6.96 (s, 2H), 6.68 (s, 2H), 5.74 (dt, J = 14.4, 6.4 Hz, 1H), 5.47 (dd, J = 14.4 
Hz, 6.4 Hz, 1H), 4.05 (br, 1H), 3.66 (m, 3H), 2.84 (m, 2H), 2.05 (m, 2H), 1.21-1.75 (m, 12H); 13C 
NMR: δ 167.8, 153.4, 149.4, 145.3, 139.5, 133.0, 130.1, 129.9, 129.1, 125.5, 100.4, 95.5, 70.7, 
55.0, 33.9, 32.3, 30.8, 30.0, 29.7, 29.4, 29.3, 29.1, 29.1; HRMS (ESI): m/z calcd for 
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C38H30BF2O4N3 [M]+ 651.30799, found 651.30567; IR (ATR): 2924, 2851, 1568, 1400, 1081 
cm-1. 
S1: Compound 6 (1030 mg, 3.90 mmol) was dissolved in a solution of 1N HCl/THF (1:2, 0.1 M) 
and the mixture heated at 75 °C for 3 hours. Then, the solvent was removed under reduced pressure. 
To mixture of crude material and NaOH (10 ml) in THF/ aq.AcONa (2:1, 0.1 M), C5H11COCl (2.2 
eq) was added and the mixture was stirred at room temperature for 1 h. Then the solvent was 
removed. To a solution of crude material in CH2Cl2 (0.2 M), dimethoxypropane (20 eq) and 
pyridinium p-toluenesulfonate (1 eq) was added at room temperature. After being stirred for 2 h, the 
reaction was quenched by sat. aq. NaHCO3 and product was extracted with EtOAc. The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure to give a residue 
that was purified by flash column chromatography (n-hexane/EtOAc = 2:1). S1 was obtained as a 
white solid (535 mg, 54%, 3 steps). 
1H NMR: δ 5.83 (ddt, J = 17.2 Hz, 10.0 Hz, 6.8 Hz, 1H), 5.34 (m, 3H), 4.15 (dd, J = 9.2 Hz, 2.0 
Hz, 1H), 3.95 (m, 2H), 3.68 (m, 1H), 2.14 (t, J = 8 Hz, 2H), 1.60 (quin, J = 7.2 Hz, 2H), 1.50 (s, 
3H), 1.43 (s, 3H), 1.30 (m, 4H), 0.89 (t, J = 6.4 Hz, 3H); 13C NMR: δ 173.0, 135.6, 118.6, 98.9, 
74.1, 62.6, 47.8, 36.8, 31.4, 28.4, 25.4, 22.4, 20.0, 13.9; HRMS (ESI): m/z calcd for 
C14H25O3N1Na1 [M+Na]+ 278.17321, found 278.17331; IR (ATR): 3286, 2956, 1644, 1549, 1380 
cm-1. 
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S4: A mixture of S1 (25 mg, 0.098 mmol) and S2 (65 mg, 0.196 mmol) in CH2Cl2 (0.02 M, Ar 
Bubbling) was prepared. After addition of 2nd generation Grubbs’ catalyst (57.4 mg, 20 mol%), the 
reaction mixture was allowed to reflux for 5 hours. The mixture was filtrated through a pad of NH-
silica and concentrated under reduced pressure. The crude material was purified by flash column 
chromatography (Hexane/EtOAc = 2/1) to give S4 as an orange film (33.2 mg, 58%). 
1H NMR: δ 8.49 (d, J =8.4 Hz, 1H), 6.58 (br, 1H), 6.17 (d, J = 8.8 Hz, 1H), 5.75 (dt, J = 15.2, 6.4 
Hz, 1H), 5.44 (dd, J = 15.2 Hz, 6.4 Hz, 1H), 5.26 (d, J = 8.0 Hz, 1H), 4.08 (m, 1H), 3.98 (m, 1H), 
3.89 (m, 1H), 3.64 (m, 1H), 3.53 (m, 2H), 2.15 (m, 2H), 2.01 (m, 2H), 1.82 (quin, J = 7.2 Hz, 2H), 
1.59 (quin, J = 7.2 Hz, 2H), 1.26-1.60 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR: δ 173.1, 144.4, 
144.1, 144.0, 136.7, 136.2, 127.5, 98.9, 74.2, 62.8, 48.0, 43.9, 36.9, 32.2, 31.4, 29.2, 29.2, 29.1, 
29.0, 28.8, 28.6, 28.5, 26.9, 25.5, 22.5, 19.9, 14.0. HRMS (ESI): m/z calcd for C26H41O6N5Na1 
[M+Na]+ 542.29545, found 542.29597.  
2c: To a mixture of S4 (33.2 mg, 0.060 mmol) in  CH2Cl2 (0.01 M), pTsOH·H2O (51 mg, 0.50 mol) 
and MeOH (0.25 ml) were added. After being stirred for 40 min, the reaction was quenched by sat. 
aq. NaHCO3 and product was extracted with EtOAc. The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure to give a residue that was purified by flash column 
chromatography (EtOAC) to give 2c as an orange film (29.4 mg, 95%). 
1H NMR: δ 8.44 (d, J =8.8 Hz, 1H), 6.91 (br, 1H), 6.44 (d, J = 7.6 Hz, 1H), 6.14 (d, J =8.8 Hz, 1H), 
5.75 (dt, J = 15.2, 6.4 Hz, 1H), 5.51 (dd, J = 15.2 Hz, 6.4 Hz, 1H), 4.28 (br, 1H), 3.90 (m, 2H), 3.68 
(d, J =7.6 Hz, 1H), 3.48 (br, 2H), 2.21 (t, J = 8.0 Hz, 1H), 2.02 (m, 2H), 1.78 (quin, J = 7.2 Hz, 2H), 
1.60 (quin, J = 7.2 Hz, 2H), 1.25 (m, 18H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR: δ 174.3, 144.3, 
144.0, 136.8, 133.9, 129.0, 123.3, 98.5, 74.4, 62.4, 54.6, 44.1, 26.8, 32.2, 31.4, 29.3, 29.2, 29.1, 
28.9, 28.4, 26.9, 25.5, 22.4, 14.0; HRMS (ESI): m/z calcd for C29H45O6N5Na1 [M+Na]+ 582.32675, 
found 582.32807.  
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2) Optical Characterization of Probes 
All solvents for spectrometry were purchased from Wako Chemical. Absorption spectra were 
recorded on a Hitachi H-3900H spectrophotometer (Hitachi Co. Ltd., Tokyo, Japan). Fluorescence 
emission spectra were recorded on Hitachi F-7000 fluorescence spectrophotometer (Hitachi Co. 
Ltd., Tokyo, Japan). Relative fluorescence quantum efficiencies of samples were obtained by 
comparing the areas under the corrected emission spectrum of Fluorescein (1 uM in 0.1 M NaOH, 
Φ = 0.85) and 3,3'-Diethylthiadicarbocyanine iodide (0.3 uM in ethanol, Φ = 0.35).4 Quantum 
yields were calculated using the following equation. The subscripts R denote the Fluorescein or 
DIDT and S denote substrates (1, 2a, 2b, 2c, 5 and KFL5).  
The optical properties of 1, 2a, 2b, 2c, 5 and KFL5 was measured under the concentration of 10 uM 
and 0.2 uM in CHCl3. (Table 1) 
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3) Standard Curves of KFL5’s Absorption and Emission 
     To calculate the right quantum yield of these new probes, the effect between probe molecule 
should be removed by a appropriate concentration, which is determined by the KFL5 standard 
curves. We choose the 0.2 uM concentration in the linear range in the emission standard curve.  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4) Biological Experiments 
Cell culture.  
COS-7 cells were grown in DMEM (Nacalai tesque) supplemented with 10 % (v/v) fetal calf serum 
(Thermo Fisher Scientific), 100 U/mL penicillin G sodium and 100 ug/mL streptomycin sulfate 
(Meiji Seika Pharma Co., Ltd.) at 37°C in a humidified incubator containing 5 % (v/v) CO2. 
Observation of fluorescence in fixed cells.   
COS-7 cells were seeded on coverslips and the distribution of fluorescence was examined when 
cells achieved 60% confluence. Cells were labeled with 10 uM C6-NBD-ceramide, 10 uM 2a or 50 
uM 1 in Hank’s Balanced Salt Solution with 0.1 % BSA, then the cells were fixed in 4% 
paraformaldehyde for 30 min. After mounting the coverslips in 50% glycerol, images of the 
fluorescence were obtained using an LSM 780 laser scanning confocal microscope (Carl Zeiss). 
NBD was excited with the 488 nm laser and emission was detected from 493 to 550 nm. KFL5 was 
excited with the 633 nm laser and emission was detected from 638 to 759 nm. The cellular 
localization of NBD and KFL5 were analyzed at an enhanced range (Gain 700) and at a standard 
range (Gain 500), respectively. Images were analyzed by ZEN software (blue edition; Carl Zeiss). 
Data were from a representative experiment repeated over three times with similar results. 
Measurement of probe 1 metabolites in cells using TLC.   
COS-7 cells on 12-well plates were incubated with 25 or 50 uM compound 1 for the indicated 
periods at 37 °C in modified Hanks’ balanced salt solution (HBSS, 400 uL; 137 mM NaCl, 5.4 mM 
KCl, 0.4 mM MgSO4, 3.3 mM Na2HPO4, 5.6 mM glucose, 0.4 mM KH2PO4, 0.7 mM CaCl2, 4.2 
mM NaHCO3, and 0.1% albumin, pH 7.4). The number of cells in each well was almost same 
(±2%) in an experiment, and cells at the sub-confluent stage (70%-80% confluent) was used in this 
assay. The labeled cells were washed twice with HBSS, and the lipids in cells were extracted by 
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adding chloroform/methanol/HCl solution as described previously5, 6 with minor modifications. The 
organic fraction including ceramide metabolites was concentrated to give a residue which was 
separated on silica gel-60 TLC plate (1-butanol/acetic acid/H2O = 3/1/1). The fluorescence 
intensities derived from NBD and KFL5 were measured using Typhoon-FLA9000 (GE Healthcare, 
Buckinghamshire, UK).  The conditions were; 473 nm excitation and 520-540 nm emission for 
NBD, 635 nm excitation and ≥665 nm emission for KFL5, PMT voltage 500, and a normal contrast 
condition (low 0 ~ high 10,000).  The positions of respective ceramide metabolites were determined 
by matching the migration distance to standards and previously reported NBD-ceramide 
metabolites, and pharmacological inhibition. The Rf values of ceramide metabolites were follows; 
C6-NBD-Cer and 2a were 0.95, NBD-caproic acid and 1 were 0.90, C6-NBD-GlcCer and C6-
NBD-GlcCer-KFL5 (and C6-NBD-GalGlcCer) were 0.75-0.80, sphingosine-KFL5 was 0.70, S1P-
KFL5 was 0.50, NBD-SM-KFL5 and SM-KFL5 were 0.30, and NBD-SM was 0.25. The bands 
responsible for C6-NBD-C1P and C6-NBD-C1P-KFL5 were very weak thus not detected. 
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Chapter Two 
To a mixture of o-iodoaniline 16 (1.34 g, 5.38 mmol) and 1,4-cyclohexanedione 
monoethylene acetal 11 (18.2 g, 117 mmol) in AcOH (5.4 mL) was added TMSCN (0.81 mL, 
6.36 mmol) at room temperature. The mixture was stirred at same temperature for 12 hours, 
and then concentrated in vacuo. Crude material was purified by flash column 
chromatography (Hexane/EtOAc = 2/1) to give 21 as colorless oil (2.2 g, quant.). 1H NMR 
(400MHz, CDCl3) δ:  7.28 (d, J = 2.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 6.86 (dd, J = 2.0 
Hz, 8.0 Hz, 1H), 3.92 (m, 4H), 3.78 (s, 1H), 3.71 (s, 3H), 2.27 (m, 2H), 2.07 (m, 2H), 1.80 
(d, J = 6.4 Hz, 4H); 13C NMR: δ 154.5, 137.4, 124.7, 121.1, 117.9, 115.2, 106.9, 91.7, 64.6, 
64.5, 64.4, 55.8, 53.8, 33.7, 30.7; 
To a solution of 21 (680 mg, 1.64 mmol) in ClCO2Me (2.7 mL) was added dried K2CO3 (2.3 
g, 16.4 mmol) at room temperature. The solution was heated at 72 ºC for 3 days and 
concentrated in vacuo. The residue was dissolved in CHCl3 and the solution was filtered 
through Celite and concentrated. The crude material was purified by flash column 
chromatography (Hexane/AcOEt = 3/1) to give 22 (633 mg, 82%) as a colorless film. 
1H NMR (400MHz, CDCl3) δ: 7.30 (d, J = 4.0 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H), 6.84 (dd, J = 4.0 
Hz, 8.8 Hz, 1H), 3.79-3.85 (m, 4H), 3.73 (s, 3H), 3.60 (s, 3H), 2.47 (m, 1H), 2.13 (m, 1H), 1.90 (m, 
2H), 1.63-1.75 (m, 4H); 13C NMR (100MHz, CDCl3) δ: 159.1, 154.2, 133.5, 131.1, 124.2, 118.5, 
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114.4, 106.1, 103.2, 64.3, 64.0, 57.4, 55.3, 53.1, 32.7, 32.4, 31.3; HRMS(ESI) m/z calcd for 
C18H21N2O5Na1I1+ [M+Na]+ 495.03928., found 495.03910;  
To a solution of 22 (100 mg, 0.212 mmol) in THF (0.265 mL) was slowly added i-PrMgCl 
(2.0 M in THF, 0.244 mL, 0.488 mmol) at 0 ºC and the mixture was stirred for 1 hour. After 
addition of 2N HCl aq. (0.265 mL), the mixture was heated at 50 ºC and stirred overnight. 
Then this mixture was cooled to room temperature. The layer was separated and the aqueous 
layer was extracted with AcOEt (3 × 100 mL). The combined organic fraction was washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (hexane/AcOEt = 2/1) to give 23 (38.0 mg, 59%) as a white 
solid. 1H NMR (400MHz, CDCl3) δ: 8.03 (br, 1H), 7.26 (dd, J = 2.8 Hz, 9.2 Hz, 1H), 7.2 
(m, 1H), 3.94-4.01 (m, 5H), 3.83 (s, 3H), 2.84-3.10 (m, 2H), 1.58-1.72 (m, 2H). 13C NMR 
(100MHz, CDCl3) δ: δ: 208.5, 159.5, 155.8, 130.9, 130.8, 130.5, 119.6, 114.4, 106.6, 64.7, 
64.4, 57.6, 55,5 53.4, 33.3, 31.8,. HRMS(ESI) m/z calcd for C16H17N1O5+ [M+Na]+ 
326.10044, found 326.10053; 
To a solution of 23 (48.0 g, 0.158 mmol) and (TMSOCH2)2 (78 uL, 0.317 mmol) in CH2Cl2 
(0.158 mL) was added TMSOTf (10 uL, 0.053 mmol) at -78 °C. After being stirred for 3 h, 
the reaction was quenched by pyridine (80 uL). After extraction by CH2Cl2, the organic 
layers were washed with brine and dried over Na2SO4 and concentration gave crude acetal 17 
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(52.2 mg, 95% ) as a pale yellow solid. 
1H NMR (400MHz, CDCl3) δ: 8.03 (br, 1H), 7.26 (dd, J = 3.2 Hz, 8.8 Hz, 1H), 7.18 (m, 1H), 4.03 
(m, 4H), 3.95 (s, 3H), 3.83 (s, 3H), 2.97 (m, 2H), 2.52 (m, 2H), 1.59-1.74 (m, 4H). 13C NMR 
(100MHz, CDCl3) δ: δ: 201.3, 156.0, 146.0, 152.1, 126.6, 122.6, 118.5, 108.0, 104.7, 68.2, 64.9, 
64.5, 55.8, 52.8, 29.9, 29.2, 26.7. HRMS(ESI) m/z calcd for C18H21N1O6+ [M+Na]+ 370.1261, 
found 370.1254. 
 
To a solution of n-BuLi (0.790 mmol, 0.50 mL) was added ethoxyacetylene (0.20 mL, 0.790 
mmol) in THF (2.7 mL) at -78 °C. After being stirred for 2 hours, a solid of 17 (137 mg, 
0.395 mmol) in CH2Cl2 (2.7 mL) was added in one portion to this reaction mixture at -78 °C. 
After being stirred for 12 hours at room temperature, the reaction was quenched with sat. 
NH4Cl. The extraction of the resulting mixture with AcOEt followed by wash of organic 
layers with brine, dried over Na2SO4 and concentration in vacuo. The residue was purified by 
flash column chromatography (hexane/AcOEt = 2/1) to give 25 (118.8 mg, 74%) as a pale 
yellow solid. 1H NMR (400MHz, CDCl3) δ: 7.56 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 2.8 Hz, 
1H), 6.79 (dd, J = 2.8 Hz, 9.2 Hz, 1H), 4.16 (m, 2H), 3.93 (m, 4H), 3.83 (s, 3H), 3.74 (s, 
3H), 2.93 (m, 1H), 2.54 (m, 2H), 2.39 (m, 1H), 2.05-2.23 (m, 2H), 1.90 (m, 2H), 1.75 (m, 
1H), 1.37 (t, J = 7.2 Hz, 1H); 13C NMR (100MHz, CDCl3) δ: 155.9, 153.5, 135.0, 134.3, 
117.5, 115.5, 108.8, 108.7, 96.5, 74.9, 74.0, 64.5, 64, 3, 57.7, 52.3, 38.7, 32.1, 31.9, 28.7, 
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24.8, 14.6; HRMS(ESI) m/z calcd for C22H27N1O7Na1 [M+Na]+ 440.16852, found 
440.16872;IR (ATR): 3422, 2952, 2261, 1698, 656 cm-1.  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